Related Experiment Videos
[Cardiac amyloidosis. General review]
1Service de médecine interne, hôpital de la Pitié, Paris, France.
Insights
Cardiac amyloidosis, a common cause of non-ischemic cardiomyopathies, presents varied symptoms. Early diagnosis and recognition of cardiac amyloidosis are crucial for appropriate treatment and improved patient outcomes.
Area of Science:
- Cardiology
- Cardiovascular Diseases
- Amyloidosis
Background:
- Cardiac amyloidosis accounts for 5-10% of non-ischemic cardiomyopathies, often presenting as restrictive cardiomyopathy.
- It can mimic other heart conditions, necessitating a high index of suspicion in unexplained cardiomyopathies in adults over forty.
- Associated symptoms like peripheral neuropathy or carpal tunnel syndrome can suggest cardiac involvement, though it may also present in isolation.
Purpose of the Study:
- To highlight the diagnostic challenges and key features of cardiac amyloidosis.
- To emphasize the importance of recognizing cardiac amyloidosis for appropriate therapeutic management.
- To discuss the implications of cardiac amyloidosis on treatment strategies and prognosis.
Main Methods:
- Review of clinical presentations, diagnostic criteria, and therapeutic implications of cardiac amyloidosis.
- Analysis of paraclinical findings including echocardiography (increased myocardial echogenicity, granular sparkling appearance, left ventricular thickening) and electrocardiography (low voltage, pseudo-infarct Q waves).
- Discussion of diagnostic confirmation methods such as extra-cardiac biopsy and serum amyloid P component scintigraphy, limiting the role of endomyocardial biopsy.
Main Results:
- Cardiac amyloidosis presents diversely, often mimicking other cardiomyopathies.
- Key diagnostic indicators include specific echocardiographic and ECG findings.
- Confirmation of amyloidosis is typically achieved via non-invasive methods, guiding crucial therapeutic decisions.
Conclusions:
- Identifying cardiac amyloidosis is critical as it contraindicates certain standard cardiac medications (digitalis, calcium channel blockers, beta-blockers).
- Treatment for AL (light-chain) amyloidosis, particularly cardiac involvement, remains challenging with poor outcomes and high mortality.
- Cardiac amyloidosis carries a poor prognosis, with transplantation being a less favorable option due to disease recurrence.
Abstract:
Cardiac amyloidosis, most often of AL type, is a non-exceptional disease as it represents 5 to 10% of non-ischemic cardiomyopathies. It realizes typically a restrictive cardiomyopathy. Nevertheless the wide diversity of possible presentation makes it a "big shammer" which must be evoked in front of every unexplained cardiopathy after the age of forty. If some associated manifestations can rapidly suggest the diagnosis, as a peripheric neuropathy especially a carpal tunnel syndrome or palpebral ecchymosis, cardiac involvement can also evolve in an apparently isolated way. The most suggestive paraclinic elements for the diagnosis are, in one hand, the increased myocardial echogenicity with a "granular sparkling" appearance seen throughout all walls of the left ventricle and, in the other hand, the association of a thickened left ventricle and a low voltage (electrocardiogram could also show pseudo-infarct Q waves). In front of such aspects, the proof of amyloidosis is brought by an extra-cardiac biopsy or by scintigraphy with labelled serum amyloid P component, so that the indications of endomyocardial biopsy are very limited today. The identification of the amyloid nature of a cardiopathy has an direct therapeutic implication: it contra-indicates the use of digitalis, calcium channel blockers and beta-blockers. The treatment of AL amyloidosis (chemotherapy with alkylant agents) remains very unsatisfactory especially in the cardiac involvement which is the most frequent cause of death (in AL amyloidosis). Last, cardiac amyloidosis is a bad indication for transplantation which results are burden by rapid progression of deposits especially in the gastro-intestinal tract and the nervous system.